AKT signaling in regulating angiogenesis

Current Cancer Drug Targets

Volumn 8, Issue 1, 2008, Pages 19-26

  Jiang, Bing Hua ^a   Liu, Ling Zhi ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

AKT; Angiogenesis; HIF 1; Tumor growth; Vascularization; VEGF

Indexed keywords

ANGIOPOIETIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; RAS PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ENZYME ACTIVATION; HUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 39049112846     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908783497122     Document Type: Review

References (141)

1. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13, 2905-2927.
2. Duronio, V.; Scheid, M. P.; Ettinger, S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal. 1998, 10, 233-239.
3. Chan, T. O.; Rittenhouse, S. E.; Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu. Rev. Biochem. 1999, 68, 965-1014.
4. Kandel, E. S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253, 210-229.
5. Jiang, B. H.; Zheng, J. Z.; Aoki, M.; Vogt, P. K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 2000, 97, 1749-1753.
6. Franke, T. F.; Hornik, C. P.; Segev, L.; Shostak, G. A.; Sugimoto, C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22, 8983-8998.
7. Alessi, D. R.; Cohen, P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998, 8, 55-62.
8. Carpenter, C. L.; Duckworth, B. C.; Auger, K. R.; Cohen, B.; Schaffhausen, B. S.; Cantley, L. C. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 1990, 265, 19704-19711.
9. Chen, H. C.; Guan, J. L. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 1994, 91, 10148-10152.
10. Izuhara, K.; Feldman, R. A.; Greer, P.; Harada, N. Interleukin-4 induces association of the c-fes proto-oncogene product with phosphatidylinositol-3 kinase. Blood 1996, 88, 3910-3918.
11. Karnitz, L. M.; Sutor, S. L.; Abraham, R. T. The Src-family kinase, Fyn, regulates the activation of phosphatidylinositol 3-kinase in an interleukin 2-responsive T cell line. J. Exp. Med. 1994, 179, 1799-1808.
12. Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 1987, 84, 5034-5037.
13. Cheng, J. Q.; Ruggeri, B.; Klein, W. M.; Sonoda, G.; Altomare, D. A.; Watson, D. K.; Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93, 3636-3641.
14. Cheng, J. Q.; Godwin, A. K.; Bellacosa, A.; Taguchi, T.; Franke, T. F.; Hamilton, T. C.; Tsichlis, P. N.; Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89, 9267-9271.
15. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399, 601-605.
16. Fulton, D.; Gratton, J. P.; McCabe, T. J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T. F.; Papapetropoulos, A.; Sessa, W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399, 597-601.
17. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a target of AKT in antiapoptotic PDGF signalling. Nature 1999, 401, 86-90.
18. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401, 82-85.
19. Kane, L. P.; Shapiro, V. S.; Stokoe, D.; Weiss, A. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 1999, 9, 601-604.
20. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278, 687-689.
21. Cheatham, B.; Vlahos, C. J.; Cheatham, L.; Wang, L.; Blenis, J.; Kahn, C. R. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 1994, 14, 4902-4911.
22. Monfar, M.; Lemon, K. P.; Grammer, T. C.; Cheatham, L.; Chung, J.; Vlahos, C. J.; Blenis, J. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol. Cell Biol. 1995, 15, 326-337.
23. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378, 785-789.
24. Klippel, A.; Reinhard, C.; Kavanaugh, W. M.; Apell, G.; Escobedo, M. A.; Williams, L. T. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell Biol. 1996, 16, 4117-4127.
25. Cantley, L. C.; Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 4240-4245.
26. Carmeliet, P.; Lampugnani, M. G.; Moons, L.; Breviario, F.; Compernolle, V.; Bono, F.; Balconi, G.; Spagnuolo, R.; Oostuyse, B.; Dewerchin, M.; Zanetti, A.; Angellilo, A.; Mattot, V.; Nuyens, D.; Lutgens, E.; Clotman, F.; de Ruiter, M. C.; Gittenberger-de Groot, A.; Poelmann, R.; Lupu, F.; Herbert, J. M.; Collen, D.; Dejana, E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98, 147-157.
27. Ong, S. H.; Hadari, Y. R.; Gotoh, N.; Guy, G. R.; Schlessinger, J.; Lax, I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl. Acad. Sci. USA 2001, 98, 6074-6079.
28. Zubilewicz, A.; Hecquet, C.; Jeanny, J. C.; Soubrane, G.; Courtois, Y.; Mascarelli, F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001, 20, 1403-1413.
29. Burgering, B. M.; Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376, 599-602.
30. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
31. Dong, G.; Chen, Z.; Li, Z. Y.; Yeh, N. T.; Bancroft, C. C.; Van Waes, C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001, 61, 5911-5918.
32. Khwaja, A.; Lehmann, K.; Marte, B. M.; Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 1998, 273, 18793-18801.
33. Kulik, G.; Klippel, A.; Weber, M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell Biol. 1997, 17, 1595-1606.
34. Oh, J. S.; Kucab, J. E.; Bushel, P. R.; Martin, K.; Bennett, L.; Collins, J.; DiAugustine, R. P.; Barrett, J. C.; Afshari, C. A.; Dunn, S. E. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia. 2002, 4, 204-217.
35. Papapetropoulos, A.; Fulton, D.; Mahboubi, K.; Kalb, R. G.; O'Connor, D. S.; Li, F.; Altieri, D. C.; Sessa, W. C. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 2000, 275, 9102-9105.
36. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4, 988-1004.
37. Shayesteh, L.; Lu, Y.; Kuo, W. L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G. B.; Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21, 99-102.
38. Kang, S.; Bader, A. G.; Zhao, L.; Vogt, P. K. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 2005, 4, 578-581.
39. Knobbe, C. B.; Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003, 13, 507-518.
40. Bellacosa, A.; de Feo, D.; Godwin, A. K.; Bell, D. W.; Cheng, J. Q.; Altomare, D. A.; Wan, M.; Dubeau, L.; Scambia, G.; Masciullo, V.; Ferrandina, G.; Benedetti, P. P.; Mancuso, S.; Neri, G.; Testa, J. R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64, 280-285.
41. Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999, 274, 21528-21532.
42. Jain, R. K.; Schlenger, K.; Hockel, M.; Yuan, F. Quantitative angiogenesis assays: progress and problems. Nat. Med. 1997, 3, 1203-1208.
43. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386, 671-674.
44. Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1-18.
45. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
46. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999, 77, 527-543.
47. Gale, N. W.; Yancopoulos, G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999, 13, 1055-1066.
48. Yancopoulos, G. D.; Klagsbrun, M.; Folkman, J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998, 93, 661-664.
49. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333, 1757-1763.
50. Fidler, I. J. Angiogenesis and cancer metastasis. Cancer J. 2000, 6(Suppl. 2), S134-S141.
51. Gupta, K.; Zhang J. Angiogenesis: a curse or cure? Postgrad. Med. J. 2005, 81, 236-242.
52. Rosen, E. M.; Lamszus, K.; Laterra, J.; Polverini, P. J.; Rubin, J. S.; Goldberg, I. D. HGF/SF in angiogenesis. Ciba Found. Symp. 1997, 212, 215-226.
53. Folkman, J. Endogenous angiogenesis inhibitors. APMIS 2004, 112, 496-507.
54. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
55. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
56. Fong, G. H.; Rossant, J.; Gertsenstein, M.; Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376, 66-70.
57. Plate, K. H.; Breier, G.; Weich, H. A.; Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359, 845-848.
58. Shalaby, F.; Rossant, J.; Yamaguchi, T. P.; Gertsenstein, M.; Wu, X. F.; Breitman, M. L.; Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376, 62-66.
59. Gerber, H. P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B. A.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273, 30336-30343.
60. Ilan, N.; Mahooti, S.; Madri, J. A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci. 1998, 111(Pt 24), 3621-3631.
61. Fujio, Y.; Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 1999, 274, 16349-16354.
62. Dumont, D. J.; Gradwohl, G.; Fong, G. H.; Puri, M. C.; Gertsenstein, M.; Auerbach, A.; Breitman, M. L. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994, 8, 1897-1909.
63. Sato, T. N.; Tozawa, Y.; Deutsch, U.; Wolburg-Buchholz, K.; Fujiwara, Y.; Gendron-Maguire, M.; Gridley, T.; Wolburg, H.; Risau, W.; Qin, Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376, 70-74.
64. Hayes, A. J.; Huang, W. Q.; Mallah, J.; Yang, D.; Lippman, M. E.; Li, L. Y. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res. 1999, 58, 224-237.
65. Lin, P.; Polverini, P.; Dewhirst, M.; Shan, S.; Rao, P. S.; Peters, K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 1997, 100, 2072-2078.
66. Vikkula, M.; Boon, L. M.; Carraway, K. L, III.; Calvert, J. T.; Diamonti, A. J.; Goumnerov, B.; Pasyk, K. A.; Marchuk, D. A.; Warman, M. L.; Cantley, L. C.; Mulliken, J. B.; Olsen, B. R. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87, 1181-1190.
67. Davis, S.; Aldrich, T. H.; Jones, P. F.; Acheson, A.; Compton, D. L.; Jain, V.; Ryan, T. E.; Bruno, J.; Radziejewski, C.; Maisonpierre, P. C.; Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87, 1161-1169.
68. Maisonpierre, P. C.; Suri, C.; Jones, P. F.; Bartunkova, S.; Wiegand, S. J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T. H.; Papadopoulos, N.; Daly, T. J.; Davis, S.; Sato, T. N.; Yancopoulos, G. D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277, 55-60.
69. Valenzuela, D. M.; Griffiths, J. A.; Rojas, J.; Aldrich, T. H.; Jones, P. F.; Zhou, H.; McClain, J.; Copeland, N. G.; Gilbert, D. J.; Jenkins, N. A.; Huang, T.; Papadopoulos, N.; Maisonpierre, P. C.; Davis, S.; Yancopoulos, G. D. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. USA 1999, 96, 1904-1909.
70. Tsigkos, S.; Koutsilieris, M.; Papapetropoulos, A. Angiopoietins in angiogenesis and beyond. Expert Opin. Investig. Drugs 2003, 12, 933-941.
71. Kim, I.; Kim, H. G.; So, J. N.; Kim, J. H.; Kwak, H. J.; Koh, G. Y. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ. Res. 2000, 86, 24-29.
72. Kim, I.; Kim, H. G.; Moon, S. O.; Chae, S. W.; So, J. N.; Koh, K. N.; Ahn, B. C.; Koh, G. Y. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ. Res. 2000, 86, 952-959.
73. Fujikawa, K.; de Aos Scherpenseel, I.; Jain, S. K.; Presman, E.; Christensen, R. A.; Varticovski, L. Role of PI 3-kinase in angiopoietin-1- mediated migration and attachment-dependent survival of endothelial cells. Exp. Cell Res. 1999, 253, 663-672.
74. Kim, I.; Kim, J. H.; Moon, S. O.; Kwak, H. J.; Kim, N. G.; Koh, G. Y. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000, 19, 4549-4552.
75. Tsigkos, S.; Zhou, Z.; Kotanidou, A.; Fulton, D.; Zakynthinos, S.; Roussos, C.; Papapetropoulos, A. Regulation of Ang2 release by PTEN/PI3-kinase/Akt in lung microvascular endothelial cells. J. Cell Physiol. 2006, 209, 239.
76. Lee, H. J.; Cho, C. H.; Hwang, S. J.; Choi, H. H.; Kim, K. T.; Ahn, S. Y.; Kim, J. H.; Oh, J. L.; Lee, G. M.; Koh, G. Y. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J. 2004, 18, 1200-1208.
77. Olsen, M. W.; Ley, C. D.; Junker, N.; Hansen, A. J.; Lund, E. L.; Kristjansen, P. E. Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. Neoplasia. 2006, 8, 364-372.
78. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004, 9, 667-676.
79. Xia, C.; Meng, Q.; Cao, Z.; Shi, X.; Jiang, B. H. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J. Cell Physiol 2006, 209, 56-66.
80. Su, J. D.; Mayo, L. D.; Donner, D. B.; Durden, D. L. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003, 63, 3585-3592.
81. Liu, L. Z.; Fang, J.; Zhou, Q.; Hu, X.; Shi, X.; Jiang, B. H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol. Pharmacol. 2005, 68, 635-643.
82. Min, J. K.; Han, K. Y.; Kim, E. C.; Kim, Y. M.; Lee, S. W.; Kim, O. H.; Kim, K. W.; Gho, Y. S.; Kwon, Y. G. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 2004, 64, 644-651.
83. Petrangolini, G.; Pratesi, G.; De Cesare, M.; Supino, R.; Pisano, C.; Marcellini, M.; Giordano, V.; Laccabue, D.; Lanzi, C.; Zunino, F. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol. Cancer Res. 2003, 1, 863-870.
84. Zhong, X. S.; Zheng, J. Z.; Reed, E.; Jiang, B. H. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem. Biophys. Res. Commun. 2004, 324, 471-480.
85. Zhu, X. F.; Xie, B. F.; Zhou, J. M.; Feng, G. K.; Liu, Z. C.; Wei, X. Y.; Zhang, F. X.; Liu, M. F.; Zeng, Y. X. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2′,4′-dihydroxy-6′-methoxy-3′,5′- dimethylchalcone), a component from Chinese herbal medicine. Mol. Pharmacol. 2005, 67, 1444-1450.
86. Sun, J. F.; Phung, T.; Shiojima, I.; Felske, T.; Upalakalin, J. N.; Feng, D.; Kornaga, T.; Dor, T.; Dvorak, A. M.; Walsh, K.; Benjamin, L. E. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc. Natl. Acad. Sci. USA 2005, 102, 128-133.
87. Coffer, P. J.; Jin, J.; Woodgett, J. R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 1998, 335(Pt 1), 1-13.
88. Chen, W. S.; Xu, P. Z.; Gottlob, K.; Chen, M. L.; Sokol, K.; Shiyanova, T.; Roninson, I.; Weng, W.; Suzuki, R.; Tobe, K.; Kadowaki, T.; Hay, N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001, 15, 2203-2208.
89. Cho, H.; Thorvaldsen, J. L.; Chu, Q.; Feng, F.; Birnbaum, M. J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001, 276, 38349-38352.
90. Yang, Z. Z.; Tschopp, O.; Hemmings-Mieszczak, M.; Feng, J.; Brodbeck, D.; Perentes, E.; Hemmings, B. A. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J. Biol. Chem. 2003, 278, 32124-32131.
91. Chen, J.; Somanath, P. R.; Razorenova, O.; Chen, W. S.; Hay, N.; Bornstein, P.; Byzova, T. V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 2005, 11, 1188-1196.
92. Ackah, E.; Yu, J.; Zoellner, S.; Iwakiri, Y.; Skurk, C.; Shibata, R.; Ouchi, N.; Easton, R. M.; Galasso, G.; Birnbaum, M. J.; Walsh, K.; Sessa, W. C. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 2005, 115, 2119-2127.
93. Cho, H.; Mu, J.; Kim, J. K.; Thorvaldsen, J. L.; Chu, Q.; Crenshaw, E. B, III.; Kaestner, K. H.; Bartolomei, M. S.; Shulman, G. I.; Birnbaum, M. J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292, 1728-1731.
94. Easton, R. M.; Cho, H.; Roovers, K.; Shineman, D. W.; Mizrahi, M.; Forman, M. S.; Lee, V. M.; Szabolcs, M.; de Jong, R.; Oltersdorf, T.; Ludwig, T.; Efstratiadis, A.; Birnbaum, M. J. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell Biol. 2005, 25, 1869-1878.
95. Brown, L. F.; Berse, B.; Jackman, R. W.; Tognazzi, K.; Manseau, E. J.; Senger, D. R.; Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993, 53, 4727-4735.
96. Byrne, A. M.; Bouchier-Hayes, D. J.; Harmey, J. H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. 2005, 9, 777-794.
97. Mazure, N. M.; Chen, E. Y.; Laderoute, K. R.; Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997, 90, 3322-3331.
98. Cao, Z.; Fang, J.; Xia, C.; Shi, X.; Jiang, B. H. trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 2004, 10, 5253-5263.
99. Fang, J.; Xia, C.; Cao, Z.; Zheng, J. Z.; Reed, E.; Jiang, B. H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005, 19, 342-353.
100. Skinner, H. D.; Zheng, J. Z.; Fang, J.; Agani, F.; Jiang, B. H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxiainducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 2004, 279, 45643-45651.
101. Huang, C.; Li, J.; Song, L.; Zhang, D.; Tong, Q.; Ding, M.; Bowman, L.; Aziz, R.; Stoner, G. D. Black raspberry extracts inhibit benzo(a)pyrene diolepoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway. Cancer Res. 2006, 66, 581-587.
102. Mirshahi, P.; Toprak, S. K.; Faussat, A. M.; Dubrulle, S.; Marie, J. P.; Soria, C.; Soria, J.; Mirshahi, M. Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways. Biochem. Biophys. Res. Commun. 2006, 349, 1003-1010.
103. Jiang, B. H.; Rue, E.; Wang, G. L.; Roe, R.; Semenza, G. L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271, 17771-17778.
104. Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
105. Dang, C. V.; Semenza, G. L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24, 68-72.
106. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67.
107. Jiang, B. H.; Agani, F.; Passaniti, A.; Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997, 57, 5328-5335.
108. Maxwell, P. H.; Dachs, G. U.; Gleadle, J. M.; Nicholls, L. G.; Harris, A. L.; Stratford, I. J.; Hankinson, O.; Pugh, C. W.; Ratcliffe, P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1997, 94, 8104-8109.
109. Ryan, H. E.; Lo, J.; Johnson, R. S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17, 3005-3015.
110. Iyer, N. V.; Kotch, L. E.; Agani, F.; Leung, S. W.; Laughner, E.; Wenger, R. H.; Gassmann, M.; Gearhart, J. D.; Lawler, A. M.; Yu, A. Y.; Semenza, G. L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12, 149-162.
111. Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 2001, 294, 1337-1340.
112. Epstein, A. C.; Gleadle, J. M.; McNeill, L. A.; Hewitson, K. S.; O'Rourke, J.; Mole, D. R.; Mukherji, M.; Metzen, E.; Wilson, M. I.; Dhanda, A.; Tian, Y. M.; Masson, N.; Hamilton, D. L.; Jaakkola, P.; Barstead, R.; Hodgkin, J.; Maxwell, P. H.; Pugh, C. W.; Schofield, C. J.; Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107, 43-54.
113. Yu, F.; White, S. B.; Zhao, Q.; Lee, F. S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 2001, 98, 9630-9635.
114. Hirota, K.; Semenza, G. L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem. Biophys. Res. Commun. 2005, 338, 610-616.
115. Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A. R.; Ryan, H. E.; Johnson, R. S.; Jefferson, A. B.; Stokoe, D.; Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000, 14, 391-396.
116. Jiang, B. H.; Jiang, G.; Zheng, J. Z.; Lu, Z.; Hunter, T.; Vogt, P. K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12, 363-369.
117. Mayo, L. D.; Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98, 11598-11603.
118. Bardos, J. I.; Chau, N. M.; Ashcroft, M. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol. Cell Biol. 2004, 24, 2905-2914.
119. Montesano, R.; Pepper, M. S.; Belin, D.; Vassalli, J. D.; Orci, L. Induction of angiogenesis in vitro by vanadate, an inhibitor of phosphotyrosine phosphatases. J. Cell Physiol 1988, 134, 460-466.
120. Soucy, N. V.; Ihnat, M. A.; Kamat, C. D.; Hess, L.; Post, M. J.; Klei, L. R.; Clark, C.; Barchowsky, A. Arsenic stimulates angiogenesis and tum origenesis in vivo. Toxicol. Sci. 2003, 76, 271-279.
121. Gao, N.; Ding, M.; Zheng, J. Z.; Zhang, Z.; Leonard, S. S.; Liu, K. J.; Shi, X.; Jiang, B. H. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. 2002, 277, 31963-31971.
122. Skinner, H. D.; Zhong, X. S.; Gao, N.; Shi, X.; Jiang, B. H. Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells. Mol. Cell Biochem. 2004, 255, 19-23.
123. Lee, M.; Hwang, J. T.; Yun, H.; Kim, E. J.; Kim, M. J.; Kim, S. S.; Ha, J. Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma. Biochem. Pharmacol. 2006, 72, 91-103.
124. Hwang, J. T.; Lee, M.; Jung, S. N.; Lee, H. J.; Kang, I.; Kim, S. S.; Ha, J. AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells. Carcinogenesis 2004, 25, 2497-2507.
125. Chen, C. J.; Wang, C. J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 1990, 50, 5470-5474.
126. Chiou, H. Y.; Hsueh, Y. M.; Liaw, K. F.; Horng, S. F.; Chiang, M. H.; Pu, Y. S.; Lin, J. S.; Huang, C. H.; Chen, C. J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995, 55, 1296-1300.
127. Chen, C. J.; Chen, C. W.; Wu, M. M.; Kuo, T. L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 1992, 66, 888-892.
128. Gao, N.; Shen, L.; Zhang, Z.; Leonard, S. S.; He, H.; Zhang, X. G.; Shi, X.; Jiang, B. H. Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell Biochem. 2004, 255, 33-45.
129. Duyndam, M. C.; Hulscher, T. M.; Fontijn, D.; Pinedo, H. M.; Boven, E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J. Biol. Chem. 2001, 276, 48066-48076.
130. Costa, M. Molecular mechanisms of nickel carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 321-337.
131. Li, J.; Davidson, G.; Huang, Y.; Jiang, B. H.; Shi, X.; Costa, M.; Huang, C. Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res. 2004, 64, 94-101.
132. Fotsis, T.; Pepper, M. S.; Aktas, E.; Breit, S.; Rasku, S.; Adlercreutz, H.; Wahala, K.; Montesano, R.; Schweigerer, L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997, 57, 2916-2921.
133. Wei, H.; Tye, L.; Bresnick, E.; Birt, D. F. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 1990, 50, 499-502.
134. Fang, J.; Zhou, Q.; Liu, L. Z.; Xia, C.; Hu, X.; Shi, X.; Jiang, B. H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1{alpha} and VEGF expression. Carcinogenesis 2007, 28, 858-864.
135. Bagli, E.; Stefaniotou, M.; Morbidelli, L.; Ziche, M.; Psillas, K.; Murphy, C.; Fotsis, T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 2004, 64, 7936-7946.
136. Fang, J.; Zhou, Q.; Shi, X. L.; Jiang, B. H. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007, 28, 713-723.
137. Hwang, D. M.; Kundu, J. K.; Shin, J. W.; Lee, H. J.; Surh, Y. J. cis-9,trans-11-Conjugated linoleic acid down-regulates phorbol ester-induced NF-{kappa}B activation and subsequent COX-2 expression in hairless mouse skin by targeting I{kappa}B kinase and PI3K-Akt. Carcinogenesis 2007, 28, 361-391.
138. Palozza, P.; Sheriff, A.; Serini, S.; Boninsegna, A.; Maggiano, N.; Ranelletti, F. O.; Calviello, G.; Cittadini, A. Lycopene induces apoptosis in immortalized fibroblasts exposed to tobacco smoke condensate through arresting cell cycle and down-regulating cyclin D1, pAKT and pBad. Apoptosis. 2005, 10, 1445-1456.
139. Akimoto, T.; Nonaka, T.; Ishikawa, H.; Sakurai, H.; Saitoh, J. I.; Takahashi, T.; Mitsuhashi, N. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 195-201.
140. Huang, S.; Houghton, P. J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003, 3, 371-377.
141. Smolewski, P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006, 17, 487-494.